1. Home
  2. MACI vs PVLA Comparison

MACI vs PVLA Comparison

Compare MACI & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MACI
  • PVLA
  • Stock Information
  • Founded
  • MACI 2024
  • PVLA 2015
  • Country
  • MACI United States
  • PVLA United States
  • Employees
  • MACI N/A
  • PVLA N/A
  • Industry
  • MACI
  • PVLA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MACI
  • PVLA Health Care
  • Exchange
  • MACI NYSE
  • PVLA Nasdaq
  • Market Cap
  • MACI 221.6M
  • PVLA 253.2M
  • IPO Year
  • MACI 2024
  • PVLA N/A
  • Fundamental
  • Price
  • MACI $10.42
  • PVLA $24.41
  • Analyst Decision
  • MACI
  • PVLA Strong Buy
  • Analyst Count
  • MACI 0
  • PVLA 7
  • Target Price
  • MACI N/A
  • PVLA $46.29
  • AVG Volume (30 Days)
  • MACI 9.6K
  • PVLA 56.0K
  • Earning Date
  • MACI 01-01-0001
  • PVLA 05-15-2025
  • Dividend Yield
  • MACI N/A
  • PVLA N/A
  • EPS Growth
  • MACI N/A
  • PVLA N/A
  • EPS
  • MACI 0.33
  • PVLA N/A
  • Revenue
  • MACI N/A
  • PVLA N/A
  • Revenue This Year
  • MACI N/A
  • PVLA N/A
  • Revenue Next Year
  • MACI N/A
  • PVLA N/A
  • P/E Ratio
  • MACI $31.66
  • PVLA N/A
  • Revenue Growth
  • MACI N/A
  • PVLA N/A
  • 52 Week Low
  • MACI $9.95
  • PVLA $11.17
  • 52 Week High
  • MACI $10.83
  • PVLA $29.27
  • Technical
  • Relative Strength Index (RSI)
  • MACI N/A
  • PVLA N/A
  • Support Level
  • MACI N/A
  • PVLA N/A
  • Resistance Level
  • MACI N/A
  • PVLA N/A
  • Average True Range (ATR)
  • MACI 0.00
  • PVLA 0.00
  • MACD
  • MACI 0.00
  • PVLA 0.00
  • Stochastic Oscillator
  • MACI 0.00
  • PVLA 0.00

About MACI MELAR ACQUISITION CORP. I

Melar Acquisition Corp I is a blank check company.

About PVLA Palvella Therapeutics Inc. Common Stock

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Share on Social Networks: